Inclusion Criteria:  Between 21 to 65 years old; Body mass index (BMI) 23 kg/m2 or higher; NAFLD or NASH as determined by liver biopsies within last 2 years with fibrosis stage F1-F4; OR Presence of steatosis and fibrosis via Transient Elastography / MRI Participants willing and able to adhere to the prohibitions and restrictions specified in the protocol; Participants willing and able to adhere to the dietary prescription as in the study protocol; Participants willing and able to provide written informed consent. Participants able to read and write English, and own a smartphone with a data plan  Exclusion Criteria:  Poorly controlled diabetes Poorly controlled hypertension Estimated glomerular filtration rate of less than 60 ml/min/1.73m2; Presence of active alcoholic liver disease, chronic viral hepatitis, drug-induced hepatitis; autoimmune hepatitis, and liver cancer; A history of Type 1 diabetes mellitus or previous admission for diabetic ketoacidosis; Recurrent urinary tract infection (2 or more over the past one year); Having any medical condition that would affect metabolism (i.e. Cushing syndrome, known active hyperthyroidism or hypothyroidism); Serious medical disease with likely life expectancy less than 5 years; Recently started on selected diabetes / hypertensive medications. Must be on stable doses. Ongoing eating disorder or significant weight loss or weight gain as defined by change of 5% or more within 12 weeks before screening visit; History of any malignancy within 5 years of screening; Women who are pregnant or plan to become pregnant; Taking alcohol above the limit recommended (i.e. consumed more than 10 g/day for women or 20 g/day for men); Participation in other clinical trial in the 30 days before randomization; Participants who cannot be followed up for at least 6 weeks (due to health situation or travel); Having allergies / intolerances to the ingredients in the prepared meals or oil-containing products of the study; Having chronic gastrointestinal disorders; Having taken antibiotics in the last 3 months; Participants with arthropathy, CVM, CVA disorder or any systemic disorder which render or when intervention may be dangerous.